XKRX950210
Market cap599mUSD
Dec 20, Last price
14,400.00KRW
1D
-4.26%
1Q
-2.44%
IPO
-71.20%
Name
Prestige Biopharma Ltd
Chart & Performance
P/E
—
P/S
0.87
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-27.52%
Rev. gr., 5y
-19.89%
Revenues
689m
+325.77%
Net income
-32.92b
L
CFO
-48.03b
L-20.32%
Profile
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||
Revenues | 689,075 325.77% | 161,841 | |||||
Cost of revenue | 29,899,176 | 92,170,188 | 64,424,222 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (29,210,101) | (92,008,347) | (64,424,222) | ||||
NOPBT Margin | |||||||
Operating Taxes | 408,679 | 763,278 | 800,662 | ||||
Tax Rate | |||||||
NOPAT | (29,618,780) | (92,771,625) | (65,224,884) | ||||
Net income | (32,921,239) -287.38% | 17,569,286 -108.31% | (211,450,137) 2,760.94% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 1,306,985 | ||||||
BB yield | -0.25% | ||||||
| Debt | |||||||
Debt current | 48,795,661 | 32,857,077 | 1,593,383 | ||||
Long-term debt | 42,446,306 | 54,524,019 | 6,905,135 | ||||
Deferred revenue | 1,592,722 | 25,427,363 | |||||
Other long-term liabilities | 1,734,456 | 1,000 | 1,000 | ||||
Net debt | (128,742,778) | (38,415,996) | (334,862,058) | ||||
| Cash flow | |||||||
Cash from operating activities | (48,027,445) | (60,273,986) | (45,907,256) | ||||
CAPEX | (27,991,302) | (65,616,682) | (68,112,635) | ||||
Cash from investing activities | 132,464,686 | (148,610,252) | (184,685,250) | ||||
Cash from financing activities | (1,464,392) | 53,183,378 | (4,503,506) | ||||
FCF | (46,243,030) | (364,867,612) | (97,129,604) | ||||
| Balance | |||||||
Cash | 228,814,545 | 301,412,431 | 303,269,577 | ||||
Long term investments | (8,829,800) | (175,615,339) | 40,090,999 | ||||
Excess cash | 219,950,291 | 125,789,000 | 343,360,576 | ||||
Stockholders' equity | 500,999,430 | 546,258,760 | 429,977,649 | ||||
Invested Capital | 386,953,134 | 506,411,890 | 115,619,592 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 60,096 | 60,096 | 60,096 | ||||
Price | 8,650.00 -8.47% | 9,450.00 -17.47% | 11,450.00 -65.30% | ||||
Market cap | 519,831,741 -8.47% | 567,908,665 -17.47% | 688,100,975 -61.63% | ||||
EV | 467,503,384 | 625,216,912 | 353,238,917 | ||||
EBITDA | (12,942,971) | (80,358,557) | (60,557,636) | ||||
EV/EBITDA | |||||||
Interest | 7,404,121 | 950,797 | 18,851 | ||||
Interest/NOPBT | |||||||